tirzepatide gastrointestinal side effects compared to semaglutide Comparative safety and of and tirzepatide: Implications for clinical decision-making in obesity management Tirzepatide versus Semaglutide Once Weekly

BMJ Open 9 , e026573 (2019)

This is the first oral GLP-1 approved for weight management, providing an average of 16.6% body weight loss in trials

increased risk of kidney, pancreas and gastrointestinal problems Getty Images Demand for weight-loss medications sold under brand names such as Ozempic and Wegovy continues to surge, with a recent study reporting one in eight Americans has taken or is currently using the drugs to treat diabetes, heart disease or obesity

At the same time, metabolic shift towards aerobic glycolysis, altered lipid metabolism, and glutamine dependency due to oncogenic signaling and hypoxic stress, further promotes tumor survival and therapy resistance (123)